Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/irbesartan - Sanofi

Next Previous
X
Search
Drug Profile

Amlodipine/irbesartan - Sanofi

Alternative Names: Aimix Combination Tablets HD; Aimix Combination Tablets LD; Amlodipine besilate/irbesartan; Aprovasc; DSP-8153; Irbesartan/amlodipine; Irbesartan/amlodipine besilate

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Handok Inc; Sanofi; Sumitomo Pharma
  • Class Antihypertensives; Biphenyl compounds; Dihydropyridines; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension
  • Phase I Unspecified

Most Recent Events

  • 21 Apr 2023 Handok completes a phase I trial for Unspecified indication (In volunteers) in South Korea (PO) (NCT05688098)
  • 23 Sep 2022 Phase-I clinical trials in Unspecified indication (In volunteers) in South Korea (PO) (NCT05688098)
  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top